FDA Green-Lights Medrobotics' Flex Robotic System For Transoral Head And Neck Surgery
Medrobotics Corp. recently received US FDA 510(k) clearance for its Flex Robotic System for transoral head and neck surgery, a market estimated at roughly $1 billion in the US alone. Although Medrobotics is only the second company to bring a robotic soft-tissue surgical system to market in the US, other novel systems are in development, including a unique robotic system for needlescopic procedures.
You may also be interested in...
Intuitive Surgical's latest earnings and procedure numbers beat analysts' expectations and further solidified its leading position in surgical robotics. But potential robotic rivals are in the wings with alternative solutions that could make robotic surgery more affordable and accessible, including Cambridge Medical Robotics, Transenterix, Titan Medical, SOFAR and J&J/Google.
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.